Cargando…
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clinical responses in patients with various cancer types.(1–5) One mechanism by which cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its ligation to PD...
Autores principales: | Tumeh, Paul C., Harview, Christina L., Yearley, Jennifer H., Shintaku, I. Peter, Taylor, Emma J. M., Robert, Lidia, Chmielowski, Bartosz, Spasic, Marko, Henry, Gina, Ciobanu, Voicu, West, Alisha N., Carmona, Manuel, Kivork, Christine, Seja, Elizabeth, Cherry, Grace, Gutierrez, Antonio, Grogan, Tristan R., Mateus, Christine, Tomasic, Gorana, Glaspy, John A., Emerson, Ryan O., Robins, Harlan, Pierce, Robert H., Elashoff, David A., Robert, Caroline, Ribas, Antoni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246418/ https://www.ncbi.nlm.nih.gov/pubmed/25428505 http://dx.doi.org/10.1038/nature13954 |
Ejemplares similares
-
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes
por: Robert, Lidia, et al.
Publicado: (2014) -
Human Physical Activity Recognition Using Smartphone Sensors
por: Voicu, Robert-Andrei, et al.
Publicado: (2019) -
Unique changes in the TCR repertoire of tumor-infiltrating lymphocytes underlie the synergy of radiotherapy with CTLA-4 blockade
por: Pilones, Karsten, et al.
Publicado: (2014) -
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011) -
Lentiviral Vector Delivery of Human Interleukin-7 (hIL-7) to Human Immune System (HIS) Mice Expands T Lymphocyte Populations
por: O'Connell, Ryan M., et al.
Publicado: (2010)